Setmelanotide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bardet Biedl Syndrome (BBS)
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Trial Timeline
Nov 23, 2018 → Mar 8, 2021
NCT ID
NCT03746522About Setmelanotide + Placebo
Setmelanotide + Placebo is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Bardet Biedl Syndrome (BBS). The current trial status is completed. This product is registered under clinical trial identifier NCT03746522. Target conditions include Bardet Biedl Syndrome (BBS), Alström Syndrome (AS).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06760546 | Phase 3 | Recruiting |
| NCT05774756 | Phase 3 | Active |
| NCT05093634 | Phase 3 | Active |
| NCT04963231 | Phase 2 | Completed |
| NCT03746522 | Phase 3 | Completed |
| NCT03287960 | Phase 3 | Completed |
| NCT02896192 | Phase 3 | Completed |
| NCT02311673 | Phase 2 | Completed |
| NCT02041195 | Phase 1/2 | Completed |
| NCT01749137 | Phase 2 | Completed |
Competing Products
3 competing products in Bardet Biedl Syndrome (BBS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide, administered subcutaneously [SC], once daily. | Rhythm Pharmaceuticals | Pre-clinical | 20 |